BiotechTube
AEON Biopharma

AEON Biopharma

AEON
United States
aeonbiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

AEON · Stock Price

USD 0.91-0.16 (-14.95%)
Market Cap: $23.6M

Historical price data

Overview

AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.

NeurologyNeuromuscular

Technology Platform

Centered on the prabotulinumtoxinA complex developed as a biosimilar to BOTOX®, combined with a proprietary 'Smart Injection Paradigm' for optimized delivery in specific indications like migraine.

Pipeline

4
4 drugs in pipeline
DrugIndicationStageWatch
ABP-450MigrainePhase 2
ABP-450 + PlaceboMigrainePhase 2
ABP-450Cervical DystoniaPhase 2
ABP-450 + PlaceboCervical DystoniaPhase 2

Funding History

2
Total raised:$105M
IPO$75M
Series A$30M

Opportunities

AEON has the opportunity to become the first-mover therapeutic biosimilar in the multi-billion dollar botulinum toxin market, addressing payer demands for cost savings and expanding patient access.
Success in its Phase 2 migraine trial could significantly de-risk the platform and attract partnership capital.

Risk Factors

The company faces high clinical trial failure risk, an unprecedented regulatory path for a neurotoxin biosimilar, and severe financial constraints requiring dilutive financing.
It must also ultimately compete against AbbVie's deeply entrenched BOTOX® franchise.

Competitive Landscape

AEON's primary competition is AbbVie's BOTOX®, with other neurotoxins (Dysport®, Xeomin®, Jeuveau®, Daxxify®) focused on cosmetics. AEON differentiates by being a pure-play therapeutic biosimilar, aiming to align with payer economics rather than cosmetic aesthetics.

More companies in Biologics / Biosimilars →More companies in United States →